Kurma Partners
VC Fund
Paris, France
Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.
- Total investments:
- 145
- Last investment:
- Lead investor:
- 48%
- Fund size:
- $236M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Kurma Partners invests in
Stages Kurma Partners invests in
Countries Kurma Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 14 contacts → | |||
Round size
- Seed
- $2.7M–$14M
- Series A
- $3.9M–$98M
- Series B
- $12M–$72M
Investment Focus
Industry
- Health Care 41 (28%)
- Biotechnology 39 (27%)
- Medical 18 (12%)
- Pharmaceutical 18 (12%)
- Therapeutics 14 (10%)
Stage
- Series A 31 (21%)
- Seed 26 (18%)
- Series B 22 (15%)
- Funding Round 15 (10%)
- Series C 9 (6%)
Country
- France 35 (24%)
- Switzerland 6 (4%)
- Spain 4 (3%)
- The Netherlands 4 (3%)
- Belgium 3 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alain Horvais
Partner
|
Partner | Total investments: 3 | Find email | |
Amanda Gett Chaperot
Partner
|
Partner | Total investments: 1 | Find email | |
Amine Marouf
Principal
|
Principal | Total investments: 2 | Find email | |
Peter Neubeck
Partner
|
Partner | Total investments: 10 | Find email | |
Philippe Peltier
Partner
|
Partner | Total investments: 19 | Find email | |
| See all 14 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics. | $33.6M / Series B / May 28, 2026 | ||
| Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms. | $12.9M / Seed / Apr 29, 2026 | ||
| Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders. | $6.4M / Seed / Mar 23, 2026 | ||
| MedinCell is an injectable slow-release drug specialist company. | $55.7M / Post-IPO Equity / Mar 05, 2026 | ||
| Alveus Therapeutics is a clinical-stage biotech company developing therapies for obesity and metabolic diseases. | $197M / Series A / Jan 08, 2026 | ||
| Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders. | $13.4M / Seed / Dec 03, 2025 | ||
| Damae Medical is a Paris, France-based medtech company. It has developed a medical device capable of seeing biological tissues in depth, at a cellular level and in vivo. This innovative optical imaging technology will especially allow dermatologists to evaluate in a precise, efficient and rapid way malignancy of tumors by a simple contact with thesurface of the skin. DAMAE Medical’s mission is to put the great power of bio-photonics at the service of opening new opportunities in medical imaging and diagnosis. | $17.4M / Series B / Nov 11, 2025 | ||
| Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC) to treat diseases with a high unmet need, including cancer. | $122.8M / Series A / Oct 16, 2025 | ||
| Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe. | $44.3M / Series C / Oct 15, 2025 | ||
| Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems. | $29.2M / Sep 25, 2025 | ||
| See all 145 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Kurma Partners invest in?
Kurma Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 145 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Kurma Partners's check size?
Kurma Partners typically joins rounds of $2.7M–$14M at Seed, $3.9M–$98M at Series A and $12M–$72M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Kurma Partners participates in.
How do I contact Kurma Partners?
Public channels for Kurma Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Kurma Partners?
The team at Kurma Partners includes Alain Horvais (Partner), Amanda Gett Chaperot (Partner) and Amine Marouf (Principal), among 14 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
